Oct 25, 2016
Biopharma markets stabilize after major drops in 3Q 2015 and 1Q 2016, with potential momentum to the upside in 4Q 2016 and 2017. IPOs have declined to the lowest level in two years, both in terms of the number of completed offerings and the amount of capital raised....
Oct 20, 2016
In the Life Sciences universe, most people think of biopharma and medical devices as two separate businesses — never shall the two paths cross. However, there are many overlaps and best practices that can be applied to both sectors. It is widely accepted that...
Oct 14, 2016
In any transaction process, two of the most important considerations for a company are: 1) where to draw the line as to what is considered confidential information 2) at what point confidential information is shared. The dividing line of what is and isn’t confidential...
Sep 28, 2016
Last week’s accelerated approval of Sarepta’s drug, Exondys 51™ (eteplirsen), for the treatment of a subset of Duchenne Muscular Dystrophy (“DMD”) patients, was an example of the amazing promise, and associated volatility within the biotech industry. We, at Locust...
Sep 21, 2016
While they sound similar, “stock” vs. “asset” purchase agreements are very different in nature and have meaningful implications for company management, boards and investors. At Locust Walk, we work with myriad small, single-product companies that are looking for help...
